XTALPI (02228) saw its stock soar 5.08% in intraday trading on Thursday, following the announcement that its incubated company, Signet Therapeutics, has secured a nomination for the 2025 Prix Galien USA Award. This prestigious recognition, often referred to as the "Nobel Prize of Pharmaceuticals," has put XTALPI's AI-powered drug discovery capabilities in the spotlight.

The nominated drug, SIGX1094R, is a groundbreaking first-in-class targeted therapy for diffuse gastric cancer. Developed using XTALPI's AI and robotic drug discovery platform, it represents a significant milestone in the field of AI-driven pharmaceuticals. The drug has already received Orphan Drug Designation and Fast Track Designation from the U.S. FDA, highlighting its potential to address a critical medical need.

This nomination not only validates XTALPI's innovative approach to drug discovery but also positions the company as a leader in the AI pharmaceutical space. With clients including 16 of the world's top 20 pharmaceutical companies and recent record-breaking partnerships, XTALPI's stock surge reflects growing investor confidence in the company's ability to revolutionize drug development through AI and robotics technology. As the company continues to advance multiple drug discovery projects, this recognition could potentially lead to increased interest from both the pharmaceutical industry and investors.